{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:13:22Z","timestamp":1774966402052,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Bach Mai Hospital","award":["5506\/Q\u0110-BM"],"award-info":[{"award-number":["5506\/Q\u0110-BM"]}]},{"name":"Bach Mai Hospital","award":["2751\/Q\u0110-BVBM"],"award-info":[{"award-number":["2751\/Q\u0110-BVBM"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40262-026-01621-9","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T09:29:07Z","timestamp":1770629347000},"page":"557-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nomograms for Therapeutic Drug Monitoring of High-Dose Amikacin in Critically Ill Patients: Insights from a Population Pharmacokinetic Analysis and Dosing Simulation"],"prefix":"10.1007","volume":"65","author":[{"given":"Thi Cuc","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinh Van","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Hoang Anh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen Tran","family":"Nam Tien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thi Hong Ngoc","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-6716","authenticated-orcid":false,"given":"Dinh Hoa","family":"Vu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoang Anh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Nhung","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong Tan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dang Minh Vuong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"The Thach","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ngoc Son","family":"Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quoc Tuan","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan Co","family":"Dao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Willem C.","family":"Alffenaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"1621_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(21)02724-0.","journal-title":"Lancet"},{"key":"1621_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13756-020-00871-x","volume":"10","author":"YR Saharman","year":"2021","unstructured":"Saharman YR, Karuniawati A, Severin JA, Verbrugh HA. Infections and antimicrobial resistance in intensive care units in lower-middle income countries: a scoping review. Antimicrob Resist Infect Control. 2021;10:22. https:\/\/doi.org\/10.1186\/s13756-020-00871-x.","journal-title":"Antimicrob Resist Infect Control"},{"key":"1621_CR3","unstructured":"European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2022\u20132020 data. Copenhagen: WHO Regional Office for Europe; 2022. Available from: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Joint-WHO-ECDC-AMR-report-2022.pdf. Accessed 27 Jan 2025."},{"key":"1621_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1089\/mdr.2023.0267","volume":"30","author":"HN Pham","year":"2024","unstructured":"Pham HN, Than TDN, Nguyen HA, Vu DH, Phung TH, Nguyen TK. Antibiotic resistance, biofilm formation, and persistent phenotype of Klebsiella pneumoniae in a Vietnamese tertiary hospital: a focus on amikacin. Microb Drug Resist. 2024;30:203\u20139. https:\/\/doi.org\/10.1089\/mdr.2023.0267.","journal-title":"Microb Drug Resist"},{"key":"1621_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13756-021-00937-4","volume":"10","author":"TVD Vu","year":"2021","unstructured":"Vu TVD, Choisy M, Do TTN, Nguyen VMH, Campbell JI, Le TH, et al. Antimicrobial susceptibility testing results from 13 hospitals in Viet Nam: VINARES 2016-2017. Antimicrob Resist Infect Control. 2021;10:78. https:\/\/doi.org\/10.1186\/s13756-021-00937-4.","journal-title":"Antimicrob Resist Infect Control"},{"key":"1621_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jiac.2021.09.001","volume":"28","author":"TN Tran","year":"2022","unstructured":"Tran TN, Vu DH, Nguyen HA, Abrams S, Bruyndonckx R, Nguyen TT, et al. Predicting mortality in intensive care unit patients infected with Klebsiella pneumoniae: a retrospective cohort study. J Infect Chemother. 2022;28:10\u20138. https:\/\/doi.org\/10.1016\/j.jiac.2021.09.001.","journal-title":"J Infect Chemother"},{"key":"1621_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/14787210.2017.1316193","volume":"15","author":"AP Zavascki","year":"2017","unstructured":"Zavascki AP, Klee BO, Bulitta JB. Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility. Expert Rev Anti Infect Ther. 2017;15:519\u201326. https:\/\/doi.org\/10.1080\/14787210.2017.1316193.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1621_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drup.2011.02.005","volume":"14","author":"JW Mouton","year":"2011","unstructured":"Mouton JW, Ambrose PG, Canton R, Drusano GL, Harbarth S, MacGowan A, et al. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Update. 2011;14:107\u201317. https:\/\/doi.org\/10.1016\/j.drup.2011.02.005.","journal-title":"Drug Resist Update"},{"key":"1621_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jgar.2017.09.019","volume":"12","author":"J Ruiz","year":"2018","unstructured":"Ruiz J, Ramirez P, Company MJ, Gordon M, Villarreal E, Concha P, et al. Impact of amikacin pharmacokinetic\/pharmacodynamic index on treatment response in critically ill patients. J Glob Antimicrob Resist. 2018;12:90\u20135. https:\/\/doi.org\/10.1016\/j.jgar.2017.09.019.","journal-title":"J Glob Antimicrob Resist"},{"key":"1621_CR10","doi-asserted-by":"publisher","unstructured":"Agence francaise de securite sanitaire des produits de sante. Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoring. Med Mal Infect. 2012;42:301\u20138. https:\/\/doi.org\/10.1016\/j.medmal.2011.07.007.","DOI":"10.1016\/j.medmal.2011.07.007"},{"key":"1621_CR11","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints and dosing of antibiotics. version 11.0. Available from: https:\/\/eucast.org\/clinical_breakpoints\/. Accessed 31 Dec 2021."},{"key":"1621_CR12","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46:1127\u201353. https:\/\/doi.org\/10.1007\/s00134-020-06050-1.","journal-title":"Intensive Care Med"},{"key":"1621_CR13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/ejhpharm-2022-003421","volume":"35","author":"KJ Frost","year":"2023","unstructured":"Frost KJ, Hamilton RA, Hughes S, Jamieson C, Rafferty P, Troise O, et al. Systematic review of high-dose amikacin regimens for the treatment of Gram-negative infections based on EUCAST dosing recommendations. Eur J Hosp Pharm. 2023;35:496\u2013504. https:\/\/doi.org\/10.1136\/ejhpharm-2022-003421.","journal-title":"Eur J Hosp Pharm"},{"key":"1621_CR14","doi-asserted-by":"publisher","first-page":"7094","DOI":"10.1128\/AAC.01032-15","volume":"59","author":"BP White","year":"2015","unstructured":"White BP, Lomaestro B, Pai MP. Optimizing the initial amikacin dosage in adults. Antimicrob Agents Chemother. 2015;59:7094\u20136. https:\/\/doi.org\/10.1128\/AAC.01032-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"1621_CR15","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2165\/00003088-200544100-00002","volume":"44","author":"F Pea","year":"2005","unstructured":"Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005;44:1009\u201334.\u00a0https:\/\/doi.org\/10.2165\/00003088-200544100-00002.","journal-title":"Clin Pharmacokinet"},{"key":"1621_CR16","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","volume":"43","author":"MP Mingeot-Leclercq","year":"1999","unstructured":"Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999;43:1003\u201312. https:\/\/doi.org\/10.1128\/AAC.43.5.1003.","journal-title":"Antimicrob Agents Chemother"},{"key":"1621_CR17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/jac\/dkv291","volume":"71","author":"C Roger","year":"2016","unstructured":"Roger C, Nucci B, Louart B, Friggeri A, Knani H, Evrard A, et al. Impact of 30 mg\/kg amikacin and 8 mg\/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. J Antimicrob Chemother. 2016;71:208\u201312. https:\/\/doi.org\/10.1093\/jac\/dkv291.","journal-title":"J Antimicrob Chemother"},{"key":"1621_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2147\/IDR.S150839","volume":"11","author":"K Sadeghi","year":"2018","unstructured":"Sadeghi K, Hamishehkar H, Najmeddin F, Ahmadi A, Hazrati E, Honarmand H, et al. High-dose amikacin for achieving serum target levels in critically ill elderly patients. Infect Drug Resist. 2018;11:223\u20138. https:\/\/doi.org\/10.2147\/IDR.S150839.","journal-title":"Infect Drug Resist"},{"key":"1621_CR19","unstructured":"Queensland Health. Aminoglycoside dosing in adults. Brisbane: State of Queensland; 2018. Available from: https:\/\/www.health.qld.gov.au\/__data\/assets\/pdf_file\/0019\/713323\/aminoglycoside-guidelines.pdf. Accessed 27 Jan 2025."},{"key":"1621_CR20","unstructured":"Bauer LA. The aminoglycoside antibiotics. Applied Clinical Pharmacokinetics. 3rd ed. New York: McGraw-Hill Education \/ Medical; 2014."},{"key":"1621_CR21","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/17512433.2019.1637253","volume":"12","author":"EM Saez Fernandez","year":"2019","unstructured":"Saez Fernandez EM, Perez-Blanco JS, Lanao JM, Calvo MV, Martin-Suarez A. Evaluation of renal function equations to predict amikacin clearance. Expert Rev Clin Pharmacol. 2019;12:805\u201313. https:\/\/doi.org\/10.1080\/17512433.2019.1637253.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1621_CR22","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179\u201384. https:\/\/doi.org\/10.1159\/000339789.","journal-title":"Nephron Clin Pract"},{"key":"1621_CR23","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. CLSI Supplement M100, USA; 2024."},{"key":"1621_CR24","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Guidance document EUCAST breakpoints in brackets. 2021. Available from: https:\/\/www.eucast.org\/bacteria\/guidance-documents\/. Accessed 2 Dec 2021."},{"key":"1621_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)--a perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85\u201394. https:\/\/doi.org\/10.1016\/j.cmpb.2003.11.003.","journal-title":"Comput Methods Programs Biomed"},{"key":"1621_CR26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/psp4.12422","volume":"8","author":"RJ Bauer","year":"2019","unstructured":"Bauer RJ. NONMEM tutorial part II: estimation methods and advanced examples. CPT Pharmacometr Syst Pharmacol. 2019;8:538\u201356. https:\/\/doi.org\/10.1002\/psp4.12422.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"1621_CR27","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometr Syst Pharmacol. 2013;2:e38. https:\/\/doi.org\/10.1038\/psp.2013.14.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"1621_CR28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN. PsN-toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241\u201357.\u00a0https:\/\/doi.org\/10.1016\/j.cmpb.2005.04.005.","journal-title":"Comput Methods Programs Biomed"},{"key":"1621_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341. https:\/\/doi.org\/10.1159\/000180580.","journal-title":"Nephron"},{"key":"1621_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","volume":"155","author":"RD Moore","year":"1987","unstructured":"Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93\u20139. https:\/\/doi.org\/10.1093\/infdis\/155.1.93.","journal-title":"J Infect Dis"},{"key":"1621_CR31","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products (EMA\/CHMP\/594085\/2015). 2016. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-use-pharmacokinetics-pharmacodynamics-development-antimicrobial-medicinal-products_en.pdf. Accessed 30 Sep 2021."},{"key":"1621_CR32","unstructured":"Joint Formulary Committee. British national formulary. Available from: https:\/\/bnf.nice.org.uk\/treatment-summary\/aminoglycosides.html. Accessed 9 Nov 2021."},{"key":"1621_CR33","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61\u2013111. https:\/\/doi.org\/10.1093\/cid\/ciw353.","journal-title":"Clin Infect Dis"},{"key":"1621_CR34","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, Tangden T, Bitterman R, Bonomo RA, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect. 2022;28:521\u201347. https:\/\/doi.org\/10.1016\/j.cmi.2021.11.025.","journal-title":"Clin Microbiol Infect"},{"key":"1621_CR35","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Guidance document on implementation and use of the revised aminoglycoside breakpoints. 2020. Available from: https:\/\/www.eucast.org\/bacteria\/guidance-documents\/. Accessed 15 Sep 2023."},{"key":"1621_CR36","doi-asserted-by":"publisher","first-page":"e02098","DOI":"10.1128\/AAC.02098-19","volume":"64","author":"C Carrie","year":"2020","unstructured":"Carrie C, Delzor F, Roure S, Dubuisson V, Petit L, Molimard M, et al. Population pharmacokinetic study of the suitability of standard dosing regimens of amikacin in critically ill patients with open-abdomen and negative-pressure wound therapy. Antimicrob Agents Chemother. 2020;64:e02098\u201319.\u00a0https:\/\/doi.org\/10.1128\/AAC.02098-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"1621_CR37","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1097\/FTD.0b013e3181f675c2","volume":"32","author":"IK Delattre","year":"2010","unstructured":"Delattre IK, Musuamba FT, Nyberg J, Taccone FS, Laterre PF, Verbeeck RK, et al. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients. Ther Drug Monit. 2010;32:749\u201356. https:\/\/doi.org\/10.1097\/FTD.0b013e3181f675c2.","journal-title":"Ther Drug Monit"},{"key":"1621_CR38","doi-asserted-by":"publisher","first-page":"106124","DOI":"10.1016\/j.ijantimicag.2020.106124","volume":"56","author":"A Marsot","year":"2020","unstructured":"Marsot A, Hraiech S, Cassir N, Daviet F, Parzy G, Blin O, et al. Aminoglycosides in critically ill patients: which dosing regimens for which pathogens? Int J Antimicrob Agents. 2020;56:106124. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106124.","journal-title":"Int J Antimicrob Agents"},{"key":"1621_CR39","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1097\/QCO.0b013e328359a4c1","volume":"25","author":"B Janson","year":"2012","unstructured":"Janson B, Thursky K. Dosing of antibiotics in obesity. Curr Opin Infect Dis. 2012;25:634\u201349. https:\/\/doi.org\/10.1097\/QCO.0b013e328359a4c1.","journal-title":"Curr Opin Infect Dis"},{"key":"1621_CR40","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ijantimicag.2011.03.022","volume":"38","author":"R Galvez","year":"2011","unstructured":"Galvez R, Luengo C, Cornejo R, Kosche J, Romero C, Tobar E, et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents. 2011;38:146\u201351. https:\/\/doi.org\/10.1016\/j.ijantimicag.2011.03.022.","journal-title":"Int J Antimicrob Agents"},{"key":"1621_CR41","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/S2666-5247(22)00338-X","volume":"4","author":"MH Pham","year":"2023","unstructured":"Pham MH, Hoi LT, Beale MA, Khokhar FA, Hoa NT, Musicha P, et al. Evidence of widespread endemic populations of highly multidrug resistant Klebsiella pneumoniae in hospital settings in Hanoi, Vietnam: a prospective cohort study. Lancet Microbe. 2023;4:e255\u201363.\u00a0https:\/\/doi.org\/10.1016\/S2666-5247(22)00338-X.","journal-title":"Lancet Microbe"},{"key":"1621_CR42","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/1120009X.2022.2153316","volume":"35","author":"B Ergun","year":"2023","unstructured":"Ergun B, Esenkaya F, Kucuk M, Yakar MN, Uzun O, Heybeli C, et al. Amikacin-induced acute kidney injury in mechanically ventilated critically ill patients with sepsis. J Chemother. 2023;35:496\u2013504. https:\/\/doi.org\/10.1080\/1120009X.2022.2153316.","journal-title":"J Chemother"},{"key":"1621_CR43","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/jpp\/rgad005","volume":"75","author":"S Li","year":"2023","unstructured":"Li S, Zhu S, Xie F. Population pharmacokinetic\/pharmacodynamic evaluations of amikacin dosing in critically ill patients undergoing continuous venovenous hemodiafiltration. J Pharm Pharmacol. 2023;75:515\u201322. https:\/\/doi.org\/10.1093\/jpp\/rgad005.","journal-title":"J Pharm Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01621-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01621-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01621-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:25:51Z","timestamp":1774963551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01621-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1621"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01621-9","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest that are directly relevant to the content of this article. Jan-Willem C. Alffenaar is an Editorial Board member of\n                      Clinical Pharmacokinetics\n                      . Jan-Willem C. Alffenaar was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Review Board of Bach Mai Hospital (Approval No. 2751\/Q\u0110-BVBM and 5506\/Q\u0110-BM).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was waived because of the retrospective nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are available from the authors on reasonable request and following the approved proposal.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The NONMEM control stream code for the final model is available in the ESM.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"TCN: data curation, methodology, investigation, formal analysis, visualization, validation, writing (original draft), writing (review and editing). DVL: data curation, methodology, investigation, formal analysis, visualization, validation, writing (original draft), writing (review and editing). HAN Jr: data curation, methodology, investigation, formal analysis, validation, writing (review and editing). NTNT: methodology, investigation, formal analysis, validation, writing (original draft), writing (review and editing). THNN: data curation, methodology, investigation, writing (review and editing). DHV: data curation, conceptualization, methodology, investigation, validation, resources, supervision, writing (review and editing). HAN: data curation, conceptualization, methodology, investigation, validation, resources, supervision, writing (review and editing). HNP: data curation, methodology, investigation, resources, validation, writing (review and editing). CTN: methodology, investigation, resources, validation, writing (review and editing). DMVN: data curation, methodology, validation, writing (review and editing). TTP: methodology, investigation, resources, validation, writing (review and editing). NSD: methodology, investigation, resources, validation, writing (review and editing). QTD: methodology, investigation, resources, validation, writing (review and editing). XCD: methodology, investigation, resources, validation, supervision, writing (review and editing). J-WCA: methodology, investigation, validation, writing (review and editing).","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}